Critical Contrast: Recursion Pharmaceuticals (RXRX) & Its Peers

Recursion Pharmaceuticals (NASDAQ:RXRXGet Rating) is one of 254 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it compare to its rivals? We will compare Recursion Pharmaceuticals to related businesses based on the strength of its risk, valuation, earnings, profitability, dividends, institutional ownership and analyst recommendations.


This table compares Recursion Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Recursion Pharmaceuticals -1,832.18% -48.07% -33.31%
Recursion Pharmaceuticals Competitors -2,250.09% -63.90% -29.64%

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Recursion Pharmaceuticals and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Recursion Pharmaceuticals 0 3 3 0 2.50
Recursion Pharmaceuticals Competitors 1557 5554 11269 206 2.54

Recursion Pharmaceuticals presently has a consensus target price of $26.00, indicating a potential upside of 248.53%. As a group, “Biological products, except diagnostic” companies have a potential upside of 95.59%. Given Recursion Pharmaceuticals’ higher possible upside, equities research analysts clearly believe Recursion Pharmaceuticals is more favorable than its rivals.

Valuation and Earnings

This table compares Recursion Pharmaceuticals and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Recursion Pharmaceuticals $10.18 million -$186.48 million -3.24
Recursion Pharmaceuticals Competitors $776.76 million $147.89 million -1.17

Recursion Pharmaceuticals’ rivals have higher revenue and earnings than Recursion Pharmaceuticals. Recursion Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

37.7% of Recursion Pharmaceuticals shares are owned by institutional investors. Comparatively, 53.5% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 16.9% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.


Recursion Pharmaceuticals rivals beat Recursion Pharmaceuticals on 9 of the 12 factors compared.

Recursion Pharmaceuticals Company Profile (Get Rating)

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. It has four clinical-stage drug candidates focused on rare, monogenic diseases; and 33 additional programs in various stages of preclinical development. Recursion Pharmaceuticals, Inc. has strategic agreements with Bayer; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. The company was founded in 2013 and is based in Salt Lake City, Utah.

Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with's FREE daily email newsletter.